Obsidian Therapeutics Inc.
OBXHealthcare|Biotechnology|US
$13.87
+4.26 (+44.43%)
About
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
Stock Price
-20.7%(1Y)
1M
+13.3%
3M
-49.6%
6M
-20.8%
YTD
-20.8%
1Y
-20.8%
3Y
-20.8%
5Y
-20.8%
Pipeline Summary
1 total trials1
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 1
Active Trials (1)
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
NCT06060613Tumor Skin
Phase 1Phase 2Recruiting
Enrollment: 254 participants
Key Facts
Market Cap$14.4M
Employees87
CEOMadan Jagasia
IPO DateAug 4, 2026
Beta2.64
52-Week Range$9.6 – $49.97
Avg Volume396,446
ExchangeNASDAQ
Websiteobsidiantx.com
Ownership
Shares Outstanding1.0M
Recent Insider Trades
ROSS ROBERT W.AWARD
Aug 3, 202637,653 shares @ $12.00
Norkunas MatthewAWARD
Aug 3, 202637,653 shares @ $12.00
Jagasia MadanAWARD
Aug 3, 202637,653 shares @ $12.00
Barrett PeterAWARD
Aug 3, 202637,653 shares @ $12.00
Hagen HeidiAWARD
Aug 3, 202637,653 shares @ $12.00
Recent News
Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting
Nov 6, 2026 · businesswire.com
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
Oct 2, 2026 · gurufocus.com
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
Oct 2, 2026 · businesswire.com
Obsidian Therapeutics (NASDAQ:OBX) Short Interest Update
Sep 28, 2026 · defenseworld.net
Obsidian Therapeutics: A $1.1 Billion Valuation Leaves Little Margin For Error
Sep 11, 2026 · seekingalpha.com
Data last updated: Nov 9, 2026, 04:25 AM